Trial Profile
An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics; Registrational
- Acronyms FUTURE 3
- Sponsors Actelion Pharmaceuticals
- 18 Feb 2017 Results published in the British Journal of Clinical Pharmacology.
- 16 Apr 2014 New trial record